22nd Century Group (XXII) Acquires GVB Biopharma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
GVB Biopharma Acquisition "Adds Scale, Scope and Diversification" - Dawson James Bullish on 22nd Century Group (XXII) with $8.50 Price Target
May 16, 2022 8:14 AM EDTDawson James analyst James McILree reiterated a Buy rating and $8.50 price target on 22nd Century Group (NASDAQ: XXII), following the company's announcement it had acquired GVB Biopharma.
The analyst comments: "22nd Century announced the acquisition of GVB Biopharma, one of the largest producers of... More
